FDA panel supports continued testing of pain drugs

(AP) -- A panel of arthritis experts has recommended that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure

The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain to protect patients. Reports of joint failure led the agency to halt studies of the drugs in 2010.

Pfizer, Johnson & Johnson and Regeneron Pharmaceuticals have asked the FDA to lift the moratorium on testing of their drugs.

"There's clearly a worrisome safety signal, but in spite of that I think there's an unmet need in certain patient populations," said panelist Dr. Sherine Gabriel, of the Mayo Medical School of Rochester of Minnesota.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA links once-promising pain drugs to bone decay

Mar 08, 2012

Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.

FDA panel backs Pfizer drug for kidney cancer

Dec 07, 2011

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

FDA panel unanimously votes down Parkinson's drug

Oct 17, 2011

A panel of federal medical specialists has unanimously voted that a drug for Parkinson's disease from Teva Pharmaceuticals has not been shown to slow progress of the debilitating neurological disease.

Recommended for you

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments